NCNA Company Profile and Key Details
NuCana plc
NCNA Stock Price Chart
Stock Price Today
NuCana plc (NCNA) stock declined over -3.48%, trading at $1.11 on NASDAQ, down from the previous close of $1.15. The stock opened at $1.14, fluctuating between $1.09 and $1.16 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Company Information
| Employees | 25 |
| Beta | 1.04 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
NuCana plc (NASDAQ: NCNA) stock price is $1.11 in the last trading session. During the trading session, NCNA stock reached the peak price of $1.16 while $1.09 was the lowest point it dropped to. The percentage change in NCNA stock occurred in the recent session was -3.48% while the dollar amount for the price change in NCNA stock was -$0.04.
The NASDAQ listed NCNA is part of Biotechnology industry that operates in the broader Healthcare sector. NuCana plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Martin Quinn
Company Sec.
Prof. Christopher B. Wood FRCS, M.D., Ph.D.
Chief Medical Officer
Mr. Hugh Stephen Griffith
Founder, Chief Executive Officer & Executive Director
Mr. Donald Munoz
Chief Financial Officer
Mr. David Harrison
Head of Translational Medicine
Ms. Theresa Bruce
Senior Vice President of Clinical Operations
Ms. Elisabeth Oelmann
Senior Vice President of Medical & Clinical Devel.
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.
Chief Medical Officer
NCNA's closing price is 15.62% higher than its 52-week low of $0.96 where as its distance from 52-week high of $19.40 is -94.28%.
Number of NCNA employees currently stands at 25.
Official Website of NCNA is: https://www.nucana.com
NCNA could be contacted at phone 441 313 571111 and can also be accessed through its website. NCNA operates from 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom.
NCNA stock volume for the day was 19.63K shares. The average number of NCNA shares traded daily for last 3 months was 155.5K.
The market value of NCNA currently stands at $4.36M with its latest stock price at $1.11 and 3.93M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com